Search and analyze individual stocks with comprehensive metrics
Genomic Valley Biotech Ltd
Fundamental Score
Genomic Valley Biotech Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of GVBL across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Strong Operating Margins (20.70%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
11 factors identified
Below-Average Return on Equity (9.68%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Premium Valuation Risk (P/E: 88.14x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.
Profit Decline Concern (-100.00%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.
Revenue Contraction (-57.14%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions and competitive positioning. Monitor recovery strategies.
Limited Growth History (-0.24% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities. Assess future growth catalysts.
Weak Earnings Growth (4.42% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.
Stagnant Profit Growth (4.42% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity. Assess transformation initiatives.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Very High P/E Ratio
Observation: Significant overvaluation risk present.
Analysis: Extremely high P/E ratios indicate potential bubble territory and high downside risk.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
Loading Peer Comparison
Finding companies in the Biotechnology sector...
Financial Statements
Comprehensive financial data for Genomic Valley Biotech Ltd
About GVBL
Business Overview
Genomic Valley Biotech Limited operates in horticulture business activities in India. The company involved in the commercial greenhouse/poly house cultivation of crops; commercial horticulture activities with aloe vera, tomato, bitter gourd, bottle gourd, brinjal, broccoli, cabbage, capsicum, carrot, cauliflower, cucumber, green chilies, onion, radish, ridge/sponge gourd, leafy vegetables, pumpkin, banana, guava, papaya, and strawberry; and commercial floriculture of flowers. It undertakes contracts for its clients for erecting greenhouses; and provides turnkey consultancy services. In addition, the company manufactures and markets bio-fertilizers; and offers farmer support apps. Further, it is involved in the operation of plant tissue culture process laboratory to produce tissue cultured plantlets. Genomic Valley Biotech Limited was incorporated in 1994 and is based in Jhajjar, India.
Company Details
Key Leadership
GVBL Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Genomic Valley Biotech Ltd (GVBL)?
As of 19 Jan 2026, 10:09 am IST, Genomic Valley Biotech Ltd (GVBL) is currently trading at ₹23.00. The stock has a market capitalization of ₹8.81 (Cr).
Is GVBL share price Overvalued or Undervalued?
GVBL is currently trading at a P/E ratio of 88.14x, compared to the industry average of 51.82x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.
What factors affect the Genomic Valley Biotech Ltd share price?
Key factors influencing GVBL's price include its quarterly earnings growth (Sales Growth: -57.14%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Genomic Valley Biotech Ltd a good stock for long-term investment?
Genomic Valley Biotech Ltd shows a 5-year Profit Growth of 4.42% and an ROE of 9.68%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing.
How does Genomic Valley Biotech Ltd compare with its industry peers?
Genomic Valley Biotech Ltd competes with major peers in the Biotechnology. Investors should compare GVBL's P/E of 88.14x and ROE of 9.68% against the industry averages to determine its competitive standing.
What is the P/E ratio of GVBL and what does it mean?
GVBL has a P/E ratio of 88.14x compared to the industry average of 51.82x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹88 for every ₹1 of annual earnings.
How is GVBL performing according to Bull Run's analysis?
GVBL has a Bull Run fundamental score of 24.6/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does GVBL belong to?
GVBL operates in the Biotechnology industry. This classification helps understand the competitive landscape and sector-specific trends affecting Genomic Valley Biotech Ltd.
What is Return on Equity (ROE) and why is it important for GVBL?
GVBL has an ROE of 9.68%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Genomic Valley Biotech Ltd generates profits from shareholders' equity.
How is GVBL's debt-to-equity ratio and what does it indicate?
GVBL has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is GVBL's dividend yield and is it a good dividend stock?
GVBL offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has GVBL grown over the past 5 years?
GVBL has achieved 5-year growth rates of: Sales Growth -0.24%, Profit Growth 4.42%, and EPS Growth 4.42%.
What is the promoter holding in GVBL and why does it matter?
Promoters hold 46.72% of GVBL shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is GVBL's market capitalization category?
GVBL has a market capitalization of ₹9 crores, placing it in the Small-cap category.
How volatile is GVBL stock?
GVBL has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for GVBL?
GVBL has a 52-week high of ₹N/A and low of ₹N/A.
What is GVBL's operating profit margin trend?
GVBL has a 5-year average Operating Profit Margin (OPM) of 20.70%, indicating the company's operational efficiency.
How is GVBL's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of -57.14% and YoY Profit Growth of -100.00%.
What is the institutional holding pattern in GVBL?
GVBL has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the stock.